Skip to main content

Table 1 Characteristics of the included studies and outcome events

From: The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis

Articles

Country

Therapeutic centre

Inclusion criteria

Drugs

Age

Male percentage (%)

Dose

ITT population

Duration

ROCI %

HSSH %

mRS 0–1%

ACD %

Gotoh 2000

Japan

183 clinical institutes

Cerebral infarction at 1 to 6 months

Cilostazol

65.2 (NC)

64.6

100 mg twice daily

533/1067

1-5 years

5.7

0.8

/

1.7

Placebo

65.1 (NC)

60.8

NC

534/1067

10.8

1.3

/

1.9

Huang 2008

China

Multiple center trial

Cerebral infarction at 1 to 6 months

Cilostazol

60.14 (10.05)

66.9

NC

360/719

1-1.5 years

3.1

0.3

/

0.8

Aspirin

60.31 (9.71)

70.5

NC

359/719

4.2

1.9

/

1.4

Guo 2009

China

Single center trail

Cerebral infarction at 1 to 6 months

Cilostazol

59.44 (10.63)

35.3

100 mg twice daily

34/68

1 year

5.9

0

/

0

Aspirin

62.06 (11.12)

35.3

100 mgonce daily

34/68

2.9

2.9

/

5.9

Shinohara 2010

Japan

278 clinical institutes

Cerebral infarction in the previous 26 weeks

Cilostazol

63.5 (9.2)

71.7

100 mg twice daily

1337/2672

1–5 years

5.4

0.7

/

1.0

Aspirin

63.4 (9.0)

71.7

81 mg once daily

1335/2672

6.6

2.3

/

1.0

Lee 2011

Korea

12 clinical institutes

Cerebral infarction within 48 h of onset

Cilostazol

63 (12)

64.1

100 mg twice daily

231/458

90 days

2.2

0

56.3

0.4

Aspirin

63 (12)

58.6

300 mg/day

227/458

4.0

0.9

56.8

0

Shimizu 2013

Japan

55 clinical institutes

Cerebral infarction within 48 h of onset

Cilostazol

66.2 (9.4)

65.7

100 mg twice daily

251/507

90 days

1.2

0.8

74.5

0

Placebo

66.6 (8.9)

68.4

NC

256/507

1.6

0.8

72.7

0

  1. ITT: intention to treat; ROCI: Recurrence of Cerebral Infarction; HSSH: Hemorrhage Stroke or Subarachnoid Hemorrhage; mRS: modifiedRankin Scale; ACD: All Case Death; NC: Not Clear.